Nodthera Ltd. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that target the [NLRP3 inflammasome](/entities/nlrp3-inflammasome) pathway for the treatment of chronic inflammatory and neurodegenerative diseases. The company was founded in 2017 and is headquartered in London, UK with operations in Cambridge, Massachusetts[@nodthera].
Nodthera's mission is to develop first-in-class small molecule inhibitors of NLRP3, a key protein complex that drives chronic inflammation in numerous diseases including Alzheimer's disease, Parkinson's disease, and inflammatory disorders.
NT-0796 is a potent, oral, brain-penetrant NLRP3 inflammasome inhibitor being developed for the treatment of Alzheimer's disease. It represents a novel approach targeting neuroinflammation, which is increasingly recognized as a central driver of neurodegenerative processes[@nlrp].
The NLRP3 inflammasome is a multi-protein complex that activates pro-inflammatory cytokines (IL-1β, IL-18) in response to various damage-associated molecular patterns (DAMPs). In Alzheimer's disease:
...
Nodthera Ltd.
Overview
Nodthera Ltd. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that target the [NLRP3 inflammasome](/entities/nlrp3-inflammasome) pathway for the treatment of chronic inflammatory and neurodegenerative diseases. The company was founded in 2017 and is headquartered in London, UK with operations in Cambridge, Massachusetts[@nodthera].
Nodthera's mission is to develop first-in-class small molecule inhibitors of NLRP3, a key protein complex that drives chronic inflammation in numerous diseases including Alzheimer's disease, Parkinson's disease, and inflammatory disorders.
NT-0796 is a potent, oral, brain-penetrant NLRP3 inflammasome inhibitor being developed for the treatment of Alzheimer's disease. It represents a novel approach targeting neuroinflammation, which is increasingly recognized as a central driver of neurodegenerative processes[@nlrp].
The NLRP3 inflammasome is a multi-protein complex that activates pro-inflammatory cytokines (IL-1β, IL-18) in response to various damage-associated molecular patterns (DAMPs). In Alzheimer's disease:
[Aβ](/proteins/amyloid-beta) oligomers and plaques activate NLRP3
Cleavage of pro-IL-1β and pro-IL-18 to active forms
Pyroptosis (inflammatory cell death)
Release of inflammatory mediators
In the brain, NLRP3 is primarily expressed in [microglia](/cell-types/microglia-neuroinflammation), the resident immune cells of the CNS. Chronic NLRP3 activation in microglia contributes to:
Sustained pro-inflammatory cytokine release
Impaired Aβ clearance
Synaptic dysfunction
Neuronal loss
Targeting NLRP3
Nodthera's approach involves direct inhibition of NLRP3 ATPase activity, which is required for inflammasome assembly and activation. This mechanism differs from: